Protective porcine influenza virus-specific monoclonal antibodies recognize similar haemagglutinin epitopes as humans.
Animals
Antibodies, Monoclonal
/ immunology
Antibodies, Viral
/ immunology
Epitopes
/ immunology
Hemagglutinin Glycoproteins, Influenza Virus
/ immunology
Hemagglutinins
/ immunology
Humans
Influenza A Virus, H1N1 Subtype
/ drug effects
Influenza A virus
/ drug effects
Influenza Vaccines
/ immunology
Influenza, Human
/ drug therapy
Swine
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
10
09
2020
accepted:
25
01
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
23
7
2021
Statut:
epublish
Résumé
Pigs are natural hosts for the same subtypes of influenza A viruses as humans and integrally involved in virus evolution with frequent interspecies transmissions in both directions. The emergence of the 2009 pandemic H1N1 virus illustrates the importance of pigs in evolution of zoonotic strains. Here we generated pig influenza-specific monoclonal antibodies (mAbs) from H1N1pdm09 infected pigs. The mAbs recognized the same two major immunodominant haemagglutinin (HA) epitopes targeted by humans, one of which is not recognized by post-infection ferret antisera that are commonly used to monitor virus evolution. Neutralizing activity of the pig mAbs was comparable to that of potent human anti-HA mAbs. Further, prophylactic administration of a selected porcine mAb to pigs abolished lung viral load and greatly reduced lung pathology but did not eliminate nasal shedding of virus after H1N1pdm09 challenge. Hence mAbs from pigs, which target HA can significantly reduce disease severity. These results, together with the comparable sizes of pigs and humans, indicate that the pig is a valuable model for understanding how best to apply mAbs as therapy in humans and for monitoring antigenic drift of influenza viruses in humans, thereby providing information highly relevant to making influenza vaccine recommendations.
Identifiants
pubmed: 33662023
doi: 10.1371/journal.ppat.1009330
pii: PPATHOGENS-D-20-02013
pmc: PMC7932163
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Viral
0
Epitopes
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Hemagglutinins
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009330Subventions
Organisme : Medical Research Council
ID : MR/P021336/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007031
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001030
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : FC001030
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007038
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007039
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001030
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : FC001030
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nature. 2009 Jun 25;459(7250):1122-5
pubmed: 19516283
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Cold Spring Harb Perspect Med. 2021 Mar 1;11(3):
pubmed: 31988203
PLoS Pathog. 2020 Jul 24;16(7):e1008628
pubmed: 32706830
Immunogenetics. 2012 Apr;64(4):303-11
pubmed: 22109540
ILAR J. 2015;56(1):44-52
pubmed: 25991697
Nature. 1981 Apr 23;290(5808):713-7
pubmed: 6163993
J Virol. 2012 Dec;86(24):13397-406
pubmed: 23015719
Clin Pharmacokinet. 2018 Mar;57(3):367-377
pubmed: 28639229
Cell. 2019 May 16;177(5):1136-1152.e18
pubmed: 31100268
J Virol. 2020 Jul 30;94(16):
pubmed: 32522849
Immunogenetics. 2016 Apr;68(4):285-93
pubmed: 26791019
J Immunol. 2013 Feb 15;190(4):1837-48
pubmed: 23319732
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30150460
Sci Transl Med. 2013 Aug 28;5(200):200ra114
pubmed: 23986398
J Immunol. 2010 Apr 1;184(7):3734-42
pubmed: 20207992
Front Immunol. 2019 Nov 08;10:2625
pubmed: 31787986
Vet Immunol Immunopathol. 2019 Sep;215:109913
pubmed: 31420069
J Clin Invest. 2015 Jul 1;125(7):2631-45
pubmed: 26011643
Science. 2012 Sep 14;337(6100):1343-8
pubmed: 22878502
Nature. 2012 Sep 27;489(7417):526-32
pubmed: 22982990
Immunogenetics. 2012 May;64(5):399-407
pubmed: 22186825
Vaccine. 2016 Oct 26;34(45):5442-5448
pubmed: 27622299
Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):17204-17210
pubmed: 32601207
Front Immunol. 2012 Jun 27;3:153
pubmed: 22754553
Nat Commun. 2014 Jul 14;5:4321
pubmed: 25027712
Vet Microbiol. 2017 Jun;205:99-105
pubmed: 28622871
Front Immunol. 2018 Apr 24;9:865
pubmed: 29740451
Immunohorizons. 2019 Oct 16;3(10):478-487
pubmed: 31619454
Vet Pathol. 2014 Mar;51(2):410-26
pubmed: 24363301
J Immunol. 2020 Aug 1;205(3):648-660
pubmed: 32591390
Vet Pathol. 2012 Nov;49(6):900-12
pubmed: 22461226
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15798-803
pubmed: 25331901
J Immunol. 2018 Jun 15;200(12):4068-4077
pubmed: 29703861
Int Immunol. 1997 Jan;9(1):189-99
pubmed: 9043960
ACS Synth Biol. 2019 May 17;8(5):989-1000
pubmed: 30935202
Vet Pathol. 1995 Nov;32(6):648-60
pubmed: 8592800
Annu Rev Anim Biosci. 2017 Feb 8;5:255-279
pubmed: 28199170
Protein Expr Purif. 2008 Nov;62(1):83-9
pubmed: 18662785
Cell. 1982 Dec;31(2 Pt 1):417-27
pubmed: 6186384
J Immunol. 2016 Jun 15;196(12):5014-23
pubmed: 27183611
EBioMedicine. 2019 Feb;40:574-582
pubmed: 30638863
PLoS Pathog. 2018 May 17;14(5):e1007017
pubmed: 29772011
Immunogenetics. 2014 Aug;66(7-8):507-11
pubmed: 24934119